Trial Profile
An Interventional, Open-label, Multicenter Phase I/IIa Clinical Trial to Investigate the Safety and Efficacy of Ascending Doses of Allogeneic ABCB5-positive Limbal Stem Cells (LSC2) for the Treatment of Limbal Stem Cell Deficiency (LSCD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs LSC-2 (Primary)
- Indications Limbal stem cell deficiency
- Focus Adverse reactions; Therapeutic Use
- Sponsors RHEACELL
- 06 Oct 2022 Planned End Date changed from 1 Sep 2021 to 1 Sep 2023.
- 06 Oct 2022 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2023.
- 09 Feb 2021 Status changed from recruiting to active, no longer recruiting.